Suchergebnisse - "Patel, Jaymala"

Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide von Haas, Naomi B, LaRiviere, Michael J, Buckingham, Thomas H, Cherkas, Yauheniya, Calara-Nielsen, Karl, Foulk, Brad, Patel, Jaymala, Gross, Steven, Smirnov, Denis, Vaughn, David J, Amaravadi, Ravi, Wellen, Kathryn E, Savitch, Samantha L, Majmundar, Krishna J, Black, Taylor A, Yee, Stephanie S, He, Miaoling, Min, Eun Jeong, Long, Qi, Jones, Jeremy O, Pal, Sumanta K, Carpenter, Erica L

“… Precision medicine approaches for managing patients with metastatic castrate-resistant prostate cancer (mCRPC) are lacking. Non-invasive approaches for …”
Volltext

Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice von Veglia, Filippo, Hashimoto, Ayumi, Dweep, Harsh, Sanseviero, Emilio, De Leo, Alessandra, Tcyganov, Evgenii, Kossenkov, Andrew, Mulligan, Charles, Nam, Brian, Masters, Gregory, Patel, Jaymala, Bhargava, Vipul, Wilkinson, Patrick, Smirnov, Denis, Sepulveda, Manuel A, Singhal, Sunil, Eruslanov, Evgeniy B, Cristescu, Razvan, Loboda, Andrey, Nefedova, Yulia, Gabrilovich, Dmitry I

“… In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of …”
Weitere Angaben

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration‐resistant prostate cancer (CRPC) von Pal, Sumanta Kumar, Patel, Jaymala, He, Miaoling, Foulk, Brad, Kraft, Katherine, Smirnov, Denis A., Twardowski, Przemyslaw, Kortylewski, Marcin, Bhargava, Vipul, Jones, Jeremy O.

“… BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and abiraterone acetate plus prednisone (abiraterone), have been approved for the …”
Volltext

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study von Cortes-Selva, Diana, Perova, Tatiana, Skerget, Sheri, Vishwamitra, Deeksha, Stein, Sarah, Boominathan, Rengasamy, Lau, Onsay, Calara-Nielsen, Karl, Davis, Cuc, Patel, Jaymala, Banerjee, Arnob, Stephenson, Tara, Uhlar, Clarissa, Kobos, Rachel, Goldberg, Jenna, Pei, Lixia, Trancucci, Danielle, Girgis, Suzette, Wang Lin, Shun Xin, Wu, Liviawati S, Moreau, Philippe, Usmani, Saad Z, Bahlis, Nizar J, van de Donk, Niels W C J, Verona, Raluca I

“… Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of …”
Weitere Angaben

Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors von Geva, Ravit, Vieito, Maria, Ramon, Jorge, Perets, Ruth, Pedregal, Manuel, Corral, Elena, Doger, Bernard, Calvo, Emiliano, Bardina, Jorge, Garralda, Elena, Brown, Regina J., Greger, James G., Wu, Shujian, Steinbach, Douglas, Yao, Tsun-Wen Sheena, Cao, Yu, Lauring, Josh, Chaudhary, Ruchi, Patel, Jaymala, Patel, Bharvin, Moreno, Victor

“… Background JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation …”
Volltext

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide von Belic, Jelena, Graf, Ricarda, Bauernhofer, Thomas, Cherkas, Yauheniya, Ulz, Peter, Waldispuehl‐Geigl, Julie, Perakis, Samantha, Gormley, Michael, Patel, Jaymala, Li, Weimin, Geigl, Jochen B., Smirnov, Denis, Heitzer, Ellen, Gross, Mitchell, Speicher, Michael R.

“… In patients with metastatic castrate‐resistant prostate cancer (mCRPC), circulating tumor DNA (ctDNA) analysis offers novel opportunities for the development …”
Volltext